Scilex Holding (SCLX) Liabilities and Shareholders Equity (2020 - 2026)

Scilex Holding (SCLX) posted quarterly Liabilities and Shareholders Equity of $293.6 million for Q1 2026, up 271.8% year-over-year from $79.0 million in Q1 2025, and down 19.55% on a QoQ basis from $365.0 million in Q4 2025.

Scilex Holding (SCLX) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends

Scilex Holding (SCLX) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $293.6 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Liabilities and Shareholders Equity rose 271.8% year-over-year to $293.6 million; the TTM figure through Mar 2026 stood at $1.0 billion (up 170.16% YoY), while the FY2025 annual figure was $365.0 million, up 292.65% from the prior year.
  • Liabilities and Shareholders Equity came in at $293.6 million for Q1 2026 at Scilex Holding, down from $365.0 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $365.0 million in Q4 2025, with the low at $79.0 million in Q1 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $138.4 million, with a median of $101.3 million recorded in 2023.
  • Across the five-year window, Liabilities and Shareholders Equity plunged 38.96% in 2023 and soared 292.65% in 2025, its largest moves.
  • Year by year, Liabilities and Shareholders Equity stood at $86.5 million in 2022, then gained by 17.08% to $101.3 million in 2023, then decreased by 8.25% to $93.0 million in 2024, then jumped by 292.65% to $365.0 million in 2025, then declined by 19.55% to $293.6 million in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $293.6 million, $365.0 million, and $275.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 116.58 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 200.89 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 136.46 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 114.02 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 128.69 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 92.50 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 56.28 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 208.00 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Scilex Holding 54.30 Mn -95.62 Mn 4.15 Mn 293.64 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 293.64 Mn
Dec 31, 2025 364.98 Mn
Sep 30, 2025 275.88 Mn
Jun 30, 2025 83.76 Mn
Mar 31, 2025 78.98 Mn
Dec 31, 2024 92.95 Mn
Sep 30, 2024 100.43 Mn
Jun 30, 2024 104.54 Mn
Mar 31, 2024 91.24 Mn
Dec 31, 2023 101.31 Mn
Sep 30, 2023 80.53 Mn
Jun 30, 2023 126.46 Mn
Mar 31, 2023 86.05 Mn
Dec 31, 2022 86.53 Mn
Sep 30, 2022 101.46 Mn
Jun 30, 2022 142.30 Mn
Mar 31, 2022 140.97 Mn
Dec 31, 2021 77.93 Mn
Sep 30, 2021 139.64 Mn
Jun 30, 2021 139.90 Mn